GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

Market Cap	457.36B -2.5%
Revenue (ttm)	39.55B +5.8%
Net Income	10.68B +12.4%
EPS	63.05 +12.4%
Shares Out	169.41M
PE Ratio	42.82
Forward PE	37.97
Dividend	57.00 (2.12%)
Ex-Dividend Date	May 29, 2026

Volume	4,014
Open	2,688.00
Previous Close	2,689.10
Day's Range	2,660.75 - 2,709.85
52-Week Range	2,088.00 - 2,899.90
Beta	0.06
Analysts	Buy
Price Target	3,081.00 (+14.12%)
Earnings Date	Aug 3, 2026

About BOM:500660

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. ...

• Industry: Pharmaceutical Preparations
• Founded: 1924
• Employees: 3,103
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500660

Financial Performance

In fiscal year 2026, BOM:500660's revenue was 38.22 billion, an increase of 1.93% compared to the previous year's 37.49 billion. Earnings were 10.36 billion, an increase of 11.69%.

Analyst Summary

According to 4 analysts, the average rating for 500660 stock is "Buy." The 12-month stock price target is ₹3,081, which is an increase of 14.12% from the latest price.

Price Target

₹3,081

(14.12% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 17, 2026

Data Sources Report a data error